Education
About Us
Working with TipRanks
Follow Us
PetVivo Holdings (PETV)
OTHER OTC:PETV
Top Page
PetVivo Holdings
(OTC:PETV)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.00
▼(-2.91% Downside)
PetVivo Holdings' overall stock score is primarily impacted by its financial performance, which faces significant challenges in profitability and cash flow. While technical indicators show some positive trends, the valuation remains difficult due to ongoing losses. The earnings call and corporate events provide some positive momentum, but the financial challenges weigh heavily on the overall score.
PetVivo Holdings (PETV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.74M
Dividend YieldN/A
Average Volume (3M)10.38K
Price to Earnings (P/E)―
Beta (1Y)-0.16
Revenue Growth33.94%
EPS Growth41.79%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.09
Shares Outstanding27,903,360
10 Day Avg. Volume14,374
30 Day Avg. Volume10,381
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue15.04
Enterprise Value/Gross Profit17.12
Enterprise Value/Ebitda-2.21
Forecast
1Y Price Target
$1.00Price Target Upside-2.91% Downside
Rating ConsensusHold
Number of Analyst Covering0
PetVivo Holdings Business Overview & Revenue Model
Company DescriptionPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
How the Company Makes MoneyPetVivo Holdings generates revenue through the sale of its flagship product, KVN, to veterinary clinics and animal hospitals. The company has established partnerships with various distributors and veterinary practices, which facilitate the distribution and administration of its products. Additional revenue streams may include licensing agreements, collaborations with veterinary professionals for product development, and potential future products that expand its portfolio in the pet health market. As awareness of pet health issues grows, and with an increasing number of pet owners seeking advanced treatment options, PetVivo is positioned to capitalize on this trend.
PetVivo Holdings Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Positive
The call highlighted strong revenue growth, significant expansion in distribution networks, and strategic partnerships, indicating positive momentum. However, challenges such as decreased gross margin and continued net losses were noted.Q1-2026 Updates
Positive Updates
Significant Revenue Growth
Total revenue for the quarter increased by 140%, reaching nearly $300,000, compared to the previous year.
Expansion in Distributor Network
The U.S. national distributor network increased sales by 192% compared to a year ago, reaching $198,000 or 67% of total revenue.
International Market Expansion
Introduction of a distributor in Mexico, with the Mexican veterinary health care market expected to grow at a CAGR of 11% to $2.4 billion by 2031.
Decrease in Operating Expenses
Operating expenses decreased by 9% to $2 million from $2.2 million in the previous year, due to strategic cost reduction and restructuring.
Uplisting to OTCQX
The company qualified to trade on the OTCQX Best Market, indicating a commitment to high financial standards and corporate governance.
Reduction in Liabilities
Total liabilities decreased by $1.2 million or 39% in the quarter, down from $5.1 million to $3.1 million compared to the same quarter a year ago.
Strategic Alliances and Partnerships
Notable partnerships with Commonwealth Markets and Digital Landia, focusing on clinical use, promotion, and AI integration in veterinary care.
Negative Updates
Decreased Gross Margin
Gross profit increased by 69%, but gross margin decreased due to the introduction of the new PrecisePRP product affecting the sales mix.
Increased Net Cash Usage
Net cash used in operating activities increased to $1.6 million from $1.5 million in the same period a year ago, due to one-time lease termination expenses and increased inventory purchases.
Continued Net Loss
Net loss available to common stockholders was $2.3 million, a 15% improvement from the loss of $2 million a year ago, but still a significant figure.
Company Guidance
During the fiscal first quarter of 2026, PetVivo reported significant growth, with revenues reaching $298,000, marking a 141% increase compared to the same quarter last year. This growth was driven by a 192% increase in sales from their North American distributor network, contributing $198,000 or 67% of the total revenue, alongside expanded in-house sales and new product offerings such as PrecisePRP. The gross profit for the quarter was $187,000, constituting 63% of the revenue, despite a decrease in gross margin due to the introduction of new products. Operating expenses were reduced by 9% to $2 million, which, combined with increased sales, led to a 10% decrease in operating loss, reducing it to $1.8 million. The company also reported a net loss of $2.3 million or $0.09 per share, which is a 15% improvement from the previous year's net loss. Additionally, PetVivo's balance sheet saw a rise in available cash to $3.3 million, mainly due to $4.7 million in net proceeds from recent financing activities, while total liabilities decreased by $1.2 million. These financial achievements reflect the company's strategic growth initiatives and operational improvements.PetVivo Holdings Financial Statement Overview
Summary
PetVivo Holdings is experiencing revenue growth, but profitability and cash flow remain significant challenges. The company has improved its leverage position but needs to focus on enhancing operational efficiency and cash flow generation to achieve financial stability.Income Statement
PetVivo Holdings has shown some revenue growth, with an 18.46% increase in the latest year. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin is relatively high at 87.84%, but the company needs to manage its operating expenses better to improve overall profitability.35
Negative
Balance Sheet
The company's debt-to-equity ratio has improved to 0.69, indicating better leverage management compared to previous years. However, the return on equity remains negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company has a reasonable level of stockholders' equity relative to its total assets.40
Negative
Cash Flow
PetVivo Holdings has a positive free cash flow to net income ratio, suggesting that it is generating cash flow relative to its net losses. However, the operating cash flow remains negative, and the company needs to improve its cash flow from operations to ensure sustainability.30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.13M | 1.13M | 968.71K | 917.16K | 115.59K | 12.58K |
| Gross Profit | 994.86K | 994.86K | 739.53K | 390.35K | -85.57K | 1.88K |
| EBITDA | -7.72M | -7.69M | -10.49M | -8.62M | -4.99M | -1.87M |
| Net Income | -8.40M | -8.40M | -10.96M | -8.70M | -4.94M | -3.75M |
Balance Sheet | ||||||
| Total Assets | 9.34M | 9.34M | 3.12M | 2.44M | 7.43M | 835.25K |
| Cash, Cash Equivalents and Short-Term Investments | 377.69K | 377.69K | 87.40K | 475.31K | 6.11M | 23.58K |
| Total Debt | 2.90M | 2.90M | 1.37M | 345.33K | 332.85K | 732.53K |
| Total Liabilities | 5.12M | 5.12M | 2.43M | 1.71M | 1.44M | 1.73M |
| Stockholders Equity | 4.22M | 4.22M | 685.95K | 725.02K | 5.99M | -896.98K |
Cash Flow | ||||||
| Free Cash Flow | -5.87M | -5.89M | -7.73M | -7.22M | -4.36M | -1.21M |
| Operating Cash Flow | -5.32M | -5.32M | -7.42M | -6.79M | -4.17M | -1.05M |
| Investing Cash Flow | -563.43K | -563.43K | -309.10K | -423.93K | -183.18K | -160.16K |
| Financing Cash Flow | 6.03M | 6.03M | 7.34M | 1.59M | 10.44M | 1.22M |
PetVivo Holdings Technical Analysis
Positive
1.03
Price Trends
0.83
Positive
0.78
Positive
0.70
Positive
Market Momentum
0.05
Negative
74.74
Negative
85.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETV, the sentiment is Positive. The current price of 1.03 is above the 20-day moving average (MA) of 0.87, above the 50-day MA of 0.83, and above the 200-day MA of 0.70, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 74.74 is Negative, neither overbought nor oversold. The STOCH value of 85.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PETV.
PetVivo Holdings Risk Analysis
PetVivo Holdings disclosed 28 risk factors in its most recent earnings report. PetVivo Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PetVivo Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $28.74M | ― | -379.92% | ― | 33.94% | 41.79% | |
48 Neutral | 25.82M | -1.83 | -140.01% | ― | 2.65% | 70.21% | |
43 Neutral | 20.22M | -3.64 | -424.89% | ― | 0.09% | 51.09% | |
43 Neutral | 8.84M | -0.18 | 0.00% | ― | 4.96% | -13.09% | |
38 Underperform | 17.08M | -0.92 | 33.53% | ― | -58.15% | 93.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
PETV
PetVivo Holdings
1.03
0.49
90.74%
IRIX
Iridex
1.19
-0.62
-34.25%
LFWD
Lifeward
0.56
-2.57
-82.11%
VVOS
Vivos Therapeutics
3.44
0.51
17.41%
ALUR
Allurion Technologies
2.20
-13.44
-85.93%
NXL
Nexalin Technology, Inc.
0.93
0.22
30.99%
PetVivo Holdings Corporate Events
Private Placements and Financing
PetVivo Holdings Completes $5M Equity Financing Initiative
Positive
Jun 24, 2025
On June 24, 2025, PetVivo Holdings, Inc. completed its equity financing initiative by receiving the final $1,000,000 from the exercise of a Purchase Option, bringing the total to $5,000,000. This completion signifies the closure of the Offering, which involved the issuance of Series B Convertible Preferred Stock, and reflects the company’s strategic efforts to bolster its financial standing through accredited investors.
Private Placements and Financing
PetVivo Holdings Secures $3 Million from Equity Offering
Positive
Jun 20, 2025
On June 20, 2025, PetVivo Holdings, Inc. received $3 million from a partial exercise of a purchase option as part of an equity financing offering for Series B Convertible Preferred Stock. The company has received a total of $4 million from this offering, with an additional $1 million anticipated by June 26, 2025. This financial move is expected to enhance the company’s operational capabilities and market positioning, as it continues to attract accredited investors under the Securities Act exemptions.
Private Placements and Financing
PetVivo Holdings Secures $200K in Equity Financing
Positive
Jun 16, 2025
On June 16, 2025, PetVivo Holdings, Inc. received $200,000 from a partial exercise of a purchase option as part of a $5 million equity financing offering. The company has previously received $800,000 and anticipates receiving the remaining $4 million by June 26, 2025. This offering involves Series B Convertible Preferred Stock and is conducted under an exemption from registration provided by the Securities Act of 1933.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.